Clinical Epigenetics

Table 2 Univariate and multivariate analyses of risk factors for OS

From: Clinical characteristics and prognostic significance of DNA methylation regulatory gene mutations in acute myeloid leukemia

Variables	Univariate analysis			Multivariate analysis
Variables	No. of patients	3-year OS (%)	P value	HR (95%CI)	P value
Gender			0.543
Male	444	61.2
Female	399	59.9
Age, years			< *0.001*	1.322 (1.002–1.745)	*0.048*
< 60	739	64.6
≥ 60	104	32.7
WBC count, *10⁹/L			*0.002*	1.390 (1.018–1.898)	*0.038*
< 100	742	62.6
≥ 100	101	45.8
Hemoglobin, g/L			0.618
< 100	581	59.9
≥ 100	262	62.1
Platelet count, *10⁹/L			0.848
< 100	686	61.0
≥ 100	157	58.7
Karyotype^a			< *0.001*		< *0.001*
Favorable	102	73.1		1
Intermediate	617	62.4		1.778 (1.185–2.666)
Adverse	91	38.7		3.600 (2.285–5.672)
2017 ELN			< *0.001*
Favorable	357	74.9
Intermediate	236	53.0
Adverse	250	47.3
HSCT			< *0.001*	0.265 (0.208–0.338)	< *0.001*
Yes	474	77.2
No	369	39.1
DMRGM	250	52.3	*0.001*	1.143 (0.904–1.444)	0.263
FLT3-ITD^Mut	153	47.5	*0.001*	1.433 (1.095–1.876)	*0.009*
NPM1^Mut	151	59.7	0.807
DNMT3A^Mut	109	40.0	< *0.001*
CEBPA^bm	108	79.3	< *0.001*	0.463 (0.303–0.709)	< *0.001*
NRAS^Mut	97	63.0	0.482
TET2^Mut	84	53.7	0.295
KIT^Mut	83	60.8	0.719
WT1^Mut	80	55.3	0.524
IDH2^Mut	78	54.8	0.375
FLT3-TKD^Mut	71	61.5	0.788
RUNX1^Mut	62	57.5	0.317
GATA2^Mut	56	59.9	0.827
KRAS^Mut	52	50.1	0.062
ASXL1^Mut	52	56.8	0.497
PTPN11^Mut	45	50.5	0.084
JAK^Mut	44	63.4	0.726
IDH1^Mut	41	60.9	0.505

OS: overall survival; WBC: white blood cell; 2017 ELN: 2017 European Leukemia Network; HSCT: hematopoietic stem cell transplantation; DMRGM: DNA methylation regulatory gene mutations. A P value of less than 0.05 is indicated in italics and bold
^aKaryotype data is unknown form 33 patients

Back to article page

ISSN: 1868-7083

Contact us

Submission enquiries: avalyn.villar@springernature.com
General enquiries: info@biomedcentral.com